

AMENDMENTS TO THE CLAIMS

The listing of claims set forth below will replace all prior versions and listings of claims in the application.

1-51 (Canceled).

52. (Currently Amended) A method of treating the inflammatory response of ulcerative colitis in a subject comprising administering to the subject an effective amount of a substance that binds to IL-13, wherein the substance that binds to IL-13 is an antibody and inhibits IL-13 activation of IL-13R α .

53-64. (Canceled)

65. (Previously Presented) The method of claim 52, wherein the subject is a mouse.

66. (Previously Presented) The method of claim 52, wherein the subject is a human.

67-68. (Canceled)

69. (Currently Amended) The method of claim 52, wherein the ulcerative colitis is oxazolone colitis.

70-84. (Canceled)

85. (Previously presented) The method of claim 52, wherein the method further comprises administering to the subject an effective amount of an antibody that binds to IL-13R α 2.